Manza · Nature communications 2023 · Within-subject crossover trial · n=20

Neural circuit selective for fast but not slow dopamine increases in drug reward.

Cited 19 times in the scientific literature.

Level 2 - randomized trial

Individual experimental crossover trial in humans with a registered trial protocol (NCT03326245).

PubMed 37938560 · doi:10.1038/s41467-023-41972-6 · record verified 2026-08-29

What was done

Twenty adults received methylphenidate orally (slow brain delivery) and intravenously (fast brain delivery) while undergoing simultaneous PET-fMRI in a registered trial (NCT03326245). The authors estimated the speed of striatal dopamine increases, assessed associated brain activity and connectivity (primary endpoint), and tested temporal associations with self-reported high ratings (secondary endpoint).

What was found

The abstract reports no numerical values, effect sizes, or confidence intervals. It reports that fast, but not slow, dopamine increases activated a corticostriatal circuit comprising the dorsal anterior cingulate cortex, insula, and their connections with the dorsal caudate, and that this activation paralleled self-reported high ratings.

Why it matters

The findings demonstrate in humans that the rate of dopamine elevation, not just total level, determines specific salience-network engagement and subjective reward, explaining why faster brain delivery increases drug abuse liability.

Limits

The sample size was small (n = 20), reducing statistical precision. The abstract does not report participant demographics, substance use history, blinding details, or exact quantitative effect sizes.

Cited by